NYSE: NVO

Explore the latest insights on NYSE: NVO and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of NYSE: NVO’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Suzhou Rigerna Therapeutics' RG002C0106 Injection Supplemental Application Accepted by China's CDE – Class 1 Chemical Drug Enters Regulatory Review
CompanyDrug

Suzhou Rigerna Therapeutics’ RG002C0106 Injection Supplemental Application Accepted by China’s CDE – Class 1 Chemical Drug Enters Regulatory Review

Data from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) show that a supplemental application for RG002C0106 Injection, submitted by Suzhou Rigerna Therapeutics Co., Ltd.…

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Novo Nordisk to Withdraw All Forms of Levemir in the UK by End‑2026 – DHSC Issues National Patient Safety Alert Mandating Insulin Switches
CompanyDrug

Novo Nordisk to Withdraw All Forms of Levemir in the UK by End‑2026 – DHSC Issues National Patient Safety Alert Mandating Insulin Switches

Novo Nordisk Licenses Nanexa's PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes
CompanyDeals

Novo Nordisk Licenses Nanexa’s PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly's Foundayo
Company

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly’s Foundayo

Novo Nordisk Completes Restructuring With Over DKK 10 Billion in Cost Savings – Semaglutide Growth Pressure Drives Pivot Toward CagriSema and a Five‑Blockbuster Pipeline
Company

Novo Nordisk Completes Restructuring With Over DKK 10 Billion in Cost Savings – Semaglutide Growth Pressure Drives Pivot Toward CagriSema and a Five‑Blockbuster Pipeline

Novo Nordisk's Once‑Weekly CagriSema Proves Superior to Tirzepatide in Head‑to‑Head Weight Loss Trial – REDEFINE 9 Delivers 21.0% Reduction vs Placebo
CompanyDrug

Novo Nordisk’s Once‑Weekly CagriSema Proves Superior to Tirzepatide in Head‑to‑Head Weight Loss Trial – REDEFINE 9 Delivers 21.0% Reduction vs Placebo

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies
CompanyDeals

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies

Novo Nordisk's Once-Weekly Sogroya Wins Positive CHMP Opinion for Children with Idiopathic Short Stature – Long-Acting Growth Hormone Set to Expand Beyond GHD in Europe
CompanyDrug

Novo Nordisk’s Once-Weekly Sogroya Wins Positive CHMP Opinion for Children with Idiopathic Short Stature – Long-Acting Growth Hormone Set to Expand Beyond GHD in Europe

Novo Nordisk Acquires Three Obesity R&D Programs from Kallyope – Non-Incretin Assets Broaden the Cardiometabolic Pipeline Beyond GLP-1
CompanyDeals

Novo Nordisk Acquires Three Obesity R&D Programs from Kallyope – Non-Incretin Assets Broaden the Cardiometabolic Pipeline Beyond GLP-1

Show More